Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)

BACKGROUND: PD-L1 expression on tumor cells is a marker of PD-1/PD-L1 antibody treatment efficacy for advanced non-small cell lung cancer (NSCLC). PD-L1 antibody (atezolizumab) prolongs overall survival (OS) compared with platinum doublet as first-line treatment for NSCLC with high PD-L1 expression....

Descripción completa

Detalles Bibliográficos
Autores principales: Seto, Takashi, Nosaki, Kaname, Shimokawa, Mototsugu, Toyozawa, Ryo, Sugawara, Shunichi, Hayashi, Hidetoshi, Murakami, Haruyasu, Kato, Terufumi, Niho, Seiji, Saka, Hideo, Oki, Masahide, Yoshioka, Hiroshige, Okamoto, Isamu, Daga, Haruko, Azuma, Koichi, Tanaka, Hiroshi, Nishino, Kazumi, Tohnai, Rie, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808447/
https://www.ncbi.nlm.nih.gov/pubmed/35105689
http://dx.doi.org/10.1136/jitc-2021-004025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808447/
https://www.ncbi.nlm.nih.gov/pubmed/35105689
http://dx.doi.org/10.1136/jitc-2021-004025

Ejemplares similares